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Abstract Fibrotic disease is a significant cause of mortal-
ity. CCN2 (connective tissue growth factor [CTGF]), a
member of the CCN family of matricellular proteins, plays
a significant role in driving the fibrogenic effects of
cytokines such as transforming growth factor β (TGFβ).
It has been proposed that other members of the CCN family
can either promote or antagonize the action of CCN2,
depending on the context. A recent elegant study published
by Bruce Riser and colleagues (Am J Pathol. 174:1725–34,
2009) illustrates that CCN3 (nov) antagonizes the fibro-
genic effects of CCN2. This paper, the subject of this
commentary, raises the intriguing possibility that CCN3
may be used as a novel anti-fibrotic therapy.
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Fibrotic disease is a significant cause of mortality, and
contributes substantially to the global health care costs.
Although fibrosis is believed to arise due to the excessive
action of fibrogenic cytokines (Krieg et al. 2007), there is
no effective treatment. Owing to its ability to promote
TGFβ signaling and fibroblast activation (Grotendorst
1997; Shi-wen et al. 2006; Kennedy et al. 2007) and its
overexpression in a wide variety of fibrotic diseases, CCN2
is considered to represent a novel target for anti-fibrotic
drug intervention (Blom et al. 2002; Leask et al. 2009).
CCN2, a cysteine-rich secretory protein of 36 to 38 kDa,
has four distinct modules which are shared by most other
members of the CCN family of matricellular proteins
(Leask and Abraham 2006). How these proteins influence
such a range of functions remains incompletely understood
but is likely related this modular nature and a complex
array of intra- and inter-molecular interactions with a
variety of regulatory proteins and ligands (including cell
surface integrins), which are likely to differ among the
different CCN proteins (Holbourn et al. 2008). For
example, it has long been recognized that CCN1 (CYR61)
and CCN2 promote, whereas CCN3 suppresses, cancer cell
growth (Perbal 2001). These results raise the possibility that
CCN3 may act to prevent the pathological actions of CCN1
or CCN2.
In a recent report, Riser and colleagues (2009) show that,
in cultured kidney mesangial cells, CCN3 is normally
expressed. TGF-β reduces CCN3 expression but increases
CCN2 and collagen type I expression. Addition of CCN3 or
CCN3 overexpression caused down-regulation of CCN2
and collagen type I. The action of CCN3 did not depend on
cell proliferation or on Smad signaling. CCN3 acted on the
type I collagen minimal promoter.
The mechanism underlying CCN3 action was not identi-
fied, but could arise due to the engagement of different
integrins resulting in the activation of different non-Smad
signaling pathways (e.g., p38, JNK, ERK) (Chen et al. 2007),
which are known to affect fibrotic responses (Leask and
Abraham 2004). Alternatively, different extracellular ligands
may be recruited to the cell surface in the presence of CCN2
alone versus the presence of CCN2 together with CCN3
(Perbal 2004). Identification of the precise elements in the
type I collagen promoter which respond to CCN3 would be
extremely informative. Nonetheless, these data support the
idea that the different combinations of CCN proteins present
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